BRAF/MEK inhibitors use for pediatric gliomas; real world experience from a resource-limited country.

ABSTRACT:

Introduction

Most pediatric low-grade-gliomas (LGG) and some high-grade-gliomas (HGG) have alterations in the RAS/MAPK pathway. Promising high tumor response rates were achieved using BRAF/MEK inhibitors, however data on their use in low-middle-income-countries (LMICs) are limited.

Methods

We retrospectively reviewed our Jordanian experience of using compassionate BRAF/MEK inhibitors in treating children with gliomas. We reviewed patients' clinical characteristics, tumor response, and side effects.

Results

Twenty patients (13 males, 7 females) were identified. Median age at diagnosis was 8.3 years (0.3-18.9years). There were fifteen LGGs, three HGGs and two grade-2 pleomorphic xanthoastrocytoma (PXA-2). Fifteen tumors were supratentorial, three posterior fossa/brainst

SUBMITTER: Abu Laban D 

PROVIDER: S-EPMC11466720 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature